For more information, visit http://www.bio-rad.com/CheckoutPrecis... For a primary antibody to be selected as a PrecisionAb Antibody, it must be highly specific, highly sensitive, and pass a rigorous validation process that includes consistent performance from batch to batch. Out of throusands of primary antibodies screened, only a few are admitted into the elite PrecisionAb Antibody category. Try PrecisionAb Antibodies and see how you can generate reproducible data without wasting time and resources on optimization. PrecisionAb Validated Western Blotting Antibodies offer researchers • High specificity and sensitivity – selected for low nonspecific binding, correct target molecular weight, and the strongest signal on a western blot • Reproducible results – stringent QC requirements ensure consistent lot-to-lot performance • Trial size for every antibody (2 applications) - conveniently evaluate western blot performance • Confidence in your data – positive control lysate provided for each antibody; validation protocol included We Are Bio-Rad. Our mission: To provide useful, high-quality products and services that advance scientific discovery and improve healthcare. At Bio-Rad, we are united behind this effort. These two objectives are the driving force behind every decision we make, from developing innovative ideas to building global solutions that help solve our customers' greatest challenges. Connect with Bio-Rad Antibodies Online: Website: https://www.bio-rad-antibodies.com/ LinkedIn: https://www.linkedin.com/showcase/bio... Facebook: https://www.facebook.com/BioRadAntibo... Twitter: https://twitter.com/BioRadAbs Pinterest: https://www.pinterest.com/BioRadAbs/ Instagram: @BioRadLabs Snapchat: @BioRadLabs
How Does an Antibody Become a PrecisionAb™ Antibody?
Video Nov 24, 2017
Study Shows HPV-vaccine Against Cervical Cancer is WorkingVideo
Girls in the first birth cohort to be offered and receive the HPV vaccine showed a lower degree of dysplasia which may eventually lead to cervical cancer than a birth cohort from 1983. This is the conclusion of a new study conducted by researchers at the University of Copenhagen, who have been the first to study the vaccine’s effect on the general population.WATCH NOW
Targeting Tumors: Challenges of Antibody-Drug ConjugatesVideo
More than two dozen ADCs are currently being used in the clinic to treat diseases like Hodgkin's lymphoma and breast cancer, and researchers are developing many more. But it's taken decades to find the right combination of drug, antibody target and linker, and then make sure the right amount of ADC hits the tumor.